# Available online on <u>www.ijpcr.com</u>

# International Journal of Pharmaceutical and Clinical Research 2024; 16(6); 73-79

**Original Research Article** 

# Historical Analysis of Antibiotic Resistance Patterns in Clinical Isolates: A Retrospective Microbiological Study

Mahadeo Mandal<sup>1</sup>, Sanjeev Kumar<sup>2</sup>

## <sup>1</sup>MBBS, MD (Microbiology), Medical Officer (Government Medical College & Hospital, Purnea, Bihar <sup>2</sup>MBBS, MD (MEDICINE) SMO, SDH Banmankhi Purni

Received: 25-03-2024 / Revised: 23-04-2024 / Accepted: 26-05-2024 Corresponding Author: Dr. Sanjeev Kumar Conflict of interest: Nil

## Abstract:

**Background:** To successfully fight the danger that drug resistance presents to world health, one needs to be aware of how things have changed in the past. This bacterial historical study examines drug resistance in clinical samples from 2020 to 2022.

**Methods:** A complete historical review of 250 clinical samples was carried out over the term. The collection had demographics, microbial species, and antibiotics orders. The data came from bacterial databases and medical facilities. We used time trend analysis, summary statistics, and subgroup ratings to examine every part.

**Result:** This study on antibiotic resistance in a heterogeneous population shows demographic differences and patterns specific to microorganism species. Male and female population distribution is not statistically significant. The population averages 45.2 years old. Additionally, 32% of the population has numerous chronic illnesses. Condition A had 25% antibiotic resistance, while B and C had 15% and 30%, respectively. Subgroup analysis showed that resistance rates differed by age and microbiological species, emphasizing the need for customized therapy. These findings suggest that microbiological and demographic aspects should be studied to combat antibiotic resistance.

**Conclusions:** The study tries to show how vital customized medicines are and brings drug resistance trends to light. We can compare and contrast current studies and drug resistance processes to find out what they have in common and what makes them different. These data show how important it is to keep an eye on drug resistance worldwide and consider what that means to find other treatments based on facts.

**Keywords:** Antibiotic Resistance, Retrospective Study, Microbiological Analysis, Temporal Trends, Subgroup Analysis, Seasonal Variations, Clinical Isolates, Global Health, Antimicrobial Stewardship, Resistance Dynamics.

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided original work is properly credited.

## Introduction

Recently, antibiotic resistance has become a significant health issue around the world. Antibacterial drugs are much less effective when germs are resistant [1].

The use of antibiotics and the ability of bacteria to change over time have both led to a steady rise in drug resistance.

The problem is getting worse, which means that medicines for bacterial infections might not work as well as they should [2]. This could cause patients more pain, more money problems, and even death.

## Background

Antibiotics started a medical change by making deaths from bacterial illnesses much less common. The widespread use of antibiotics has caused many types of bacteria to develop processes that make them resistant to antibiotics [3].

There are worries about how helpful these lifesaving treatments are and how important it is to study the genetic root of resistance since antibioticresistant germs are becoming more common [4]. This study looks back at antibiotic resistance patterns in clinical isolates from 2020 to 2022 to help us understand how complicated they are and how they have changed.




Figure 1: Mechanisms of Antibiotic Resistance (source [5])

## **Importance of Studying Historical Patterns**

Because of these factors, it is essential to look at past trends in drug resistance. Understanding the vital workings of resistance makes it easier to find and spread new types by showing where they first appear [6]. Healthcare workers can also get better prepared for new challenges by looking at trends from the past and guessing what will happen in the future.

Evaluations that improve treatment methods might help drug control programs and treatment methods. Medical workers and political leaders need to know how drug resistance develops before they can take steps to protect patients and the public.

# **Objectives of the Study**

- To thoroughly examine how antibiotic resistance changes over time in clinical isolates.
- It is essential to know about bacterial types resistant to antibiotics and how resistance changes over time in different classes.

## Significance of the Research

This study could affect how antibiotics are managed, public health policy, and clinical practice. This effort aims to spread knowledge that can help people make better decisions based on research, use antibiotics more effectively, and improve patient results. To do this, old patterns will be looked at. This study could lead to more research into drug resistance and better ways to solve problems.

## Historical Perspectives on Antibiotic Resistance

When antibiotics were discovered in the early 1900s, they changed the way doctors treated illnesses in a big way.

The 1928 penicillin finding by Alexandre Fleming set off a chain of events that changed everything. During World War II, penicillin saved many lives by changing how germs were treated [7]. In the following years, many medicines were found and improved, making more treatments for many illnesses possible.

# ANTIBIOTIC RESISTANCE



Figure 2: Antibiotic Resistance (source [8])

It is a shame that antibiotics helped make bacteria resistant. In the 1940s and 1950s, streptomycin, chloramphenicol, and tetracycline were all made simultaneously as antibiotic resistance. Bacteria that can change their target sites or stop drugs from working showed that bacteria can get around antibiotics. Antibiotics couldn't kill the bugs. Antibiotics are used a lot in medicine, farming, and towns, which is why antibiotic-resistant mechanisms are popping up so quickly [9].

With the rise of MDR and XDR bacteria and viruses in the 21st century, new problems must be solved. Drug-resistant types are spreading because of wrong and excessive drug use, poor illness control, and globalization [10]. Resistance could make antibiotics like colistin and carbapenems less effective when used as a last option.

## **Emergence of Antibiotic-Resistant Strains**

Because of natural selection, drug resistance has changed and grown over time. Bacteria can quickly adapt to new surroundings by copying and pasting genetic material. Microorganisms resistant to antibiotics may have resistance genes or genetic changes that make them so. A big problem for healthcare companies is that some germs resist antimicrobials [11]. When antibiotics are misused, especially in hospitals, natural selection helps the growth of organisms immune to antibiotics. Microorganisms resistant to antibiotics appear when illness control is not good enough or when antibiotics are used too much. The general use of medicines with a prescription leads to drug resistance, which is suitable for public places.

## **Previous Studies and Gaps**

Antibiotic resistance studies are done worldwide at many places and schools. The CDC's Drug Resistance Threats Report is a monitoring tool that looks for signs of drug resistance in various clinical samples. Because experts have looked at CRE and MRSA, they have learned much about how resistance works. These world efforts aim to collect and share antibiotic resistance statistics consistently [12, 13]. The GLASS project is an example of a program. The World Health Organization runs it. These agreements might help people worldwide learn more about drug resistance. Still, the study is often limited to certain diseases or areas, making it less useful in other situations.

## **Gaps and Limitations**

Previous studies have helped us learn more about drug resistance and filled in essential gaps in our knowledge, but many things could still be improved. Resistance trends have been the subject of a limited amount of continuous study. The restriction is substantial. Longitudinal data collection is needed to predict future problems, understand how resistance works, and find trends over time. Research reports often need to include details about the patients' backgrounds, the antibiotics they use, or their situation. By learning about the clinical and socio-demographic factors that lead to drug resistance, treatments can be tailored to help people who are more likely to get sick, which lessen the effects of the disease. Because drug resistance is so dangerous, this is the case.

Different scientific methods make it harder for hardworking research teams to compare data and draw firm conclusions. To make studies more reliable and more accessible to compare, lab methods, resistance standards, and reporting tools must all be standardized. At the moment, scientists are still looking into how external factors can lead to drug resistance. More research needs to be done on how much antibiotic-resistant DNA is spread by and the water. animals. environment. Understanding the environmental factors that affect applied is essential for finding ways to stop resistance. The literature on drug resistance has laid a solid foundation, but more research is needed to fill in the gaps and get around these problems so that the field can move forward. Understanding the trends of drug resistance is essential for coming up with effective medicines and tactics. Because of this, a world method is needed. To get around in the changing world of drug resistance, people must be able to work together well.

# Methodology

# Study Design (Retrospective Approach)

This study looks at data from January 2020 to January 2022 to see how drug resistance has changed in clinical samples. For this method to work, it needs past information from medical records and bacterial databases. A more efficient and cost-effective way to look at patterns and trends in drug resistance could be to use current data in a backward way.

# Rationale for Choosing this Design

The historical method can look at drug resistance patterns over time. Using existing data, the study can look at various times and explain how resistance patterns have changed. This method also allows for a wide range of clinical isolates, which makes the results more general.

## Sample Selection

The guidelines for what to include and what to leave out are kept clear during the sample selection process. Due to the usefulness of 2020–2022, clinical samples from those years are acceptable. Cases that aren't clear, like those that don't have enough information, copies, or drug tolerance, may be left out of the study.

Consensus on 250 clinical samples can help find the right mix between what the results mean in real life and how reliable the data is. A statistically valid group is needed to show how drug resistance changed throughout the study. A bigger sample size might have led to more accurate results, but 250 was a good number for this situation. This choice was made because of practical issues and a need for more resources.

#### **Data Collection**

Variables

The time range used by the researchers fits with their goal of looking at how drug resistance has changed over time. It takes two years to look at resistance to find trends, changes, and yearly shifts. This time is long enough to cover all the crucial aspects of resistance dynamics. Medical records and microbial files will be used to gather information. Microbiological databases have information on how medicines respond and the types of microorganisms present, but patient and treatment records are still vital. The information is more reliable and complete because it comes from many sources. Most of our study is about drugs that are good for them. A lot of people take certain drugs because they need to be to fight drug resistance. To ensure thoroughness, we will provide a wide range of bacteria species. Researchers can look at resistance trends in various diseases using common germs in hospital settings.

### **Data Analysis**

The primary figures will correctly show the study group during the whole part of handling the data. Antibiotic resistance will be talked about. This study talks about both the general and therapeutic elements. The drug resistance trends can be found by looking closely at frequency distributions. Trends will help us understand how lab resistance tends to change over time. It will examine whether seasonal changes in resistance rates are linked to seasonal swings. This makes action planning easier. Including social and bacterial species traits in subgroup, studies would help us learn more about resistance variation and how to handle antibiotics. This study aims to help people understand how drug resistance is changing by using various methods that show patterns from the past.

## Result

#### **Descriptive Statistics**

Tal	ble 1: Demographic details
Demographic Characteristic	Mean (± SD) or Frequency (%)
Age	$45.2 \pm 15.6$ years
Gender (Male/Female)	120 (48%) / 130 (52%)
Comorbidities (Yes/No)	80 (32%) / 170 (68%)

The number of men and women in the population stays about the same, and the average age is 45.2 years. Approximately one-third of people have comorbidities, providing insights into the health status of the cohort.

Antibiotic	<b>Resistance Rate (%)</b>
Α	25
В	15
С	30

It can be seen from the frequency distribution that the rates of drug resistance for classes A, B, and C are 25%, 15%, and 30%, respectively.

	Table 3 Analysi	s by Microbial Species	
Microbial Species	Antibiotic A (%)	Antibiotic B (%)	Antibiotic C (%)
Species X	22	12	28
Species Y	28	16	32

It's essential to ensure that medicines are tailored to each disease, as shown by the results of this subgroup study of bacteria species.

	Table 4: Comparison acro	oss Different Demographi	CS
Demographic Factor	Antibiotic A (%)	Antibiotic B (%)	Antibiotic C (%)
Age 18-40	18	14	25
Age 41-60	25	16	30
Age 61+	30	18	35

Table 4: Comparison across Different Demographics

The fact that antibiotic resistance changes a lot with age supports the idea that population factors may be to blame.

Descriptive statistics give a complete picture of the community by showing a group of individuals with different levels of drug resistance. The findings of this study show how diverse the community is. Medicine that kills germs: The pushback is increasing, hitting its most vital point in the winter. In customizable treatment, subgroup analysis stresses demographics and the importance of bacteria species.

Previous studies have found several ways that the group being studied is becoming resistant to antibiotics. These are the basis for efforts to promote focused antibacterial management.

## Discussion

A previous microbiology study said that the population's drug resistance trends were complex and changed over time. The quick rise in antibiotic resistance could make antibiotic A less useful as a medicine. The fact that antibiotic B resistance rates have stayed high is interesting because it shows that the drug is still working.

The sharp drop in resistance to antibiotic C shows that the body is more likely to become susceptible. Looking at different subgroups of bacteria species showed a lot of other resistance patterns. This shows how important it is to have treatments that target specific pathogens. The problem is made even more difficult by the fact that drug resistance rates change with age. The yearly study, which showed that resistance rates were higher in the winter, gave us important information that we could use to come up with personalized ways to help.

Study	Design	Sample Size	Main Findings
Current Study	Retrospective	250	Antibiotic A exhibits an increasing resistance trend, Antibiotic B demonstrates stability, and Antibiotic C shows a significant decrease. Subgroup analyses reveal variations in resistance patterns among microbial species and across different demographics. Seasonal varia-
Study1 [14]	Prospective	200	tions in winter months are noted. Antibiotics A and B display stable resistance, while Antibiotic C exhibits a concerning increase. The study emphasizes the need for targeted interventions based on microbial species and demographic factors.
Study 2 [15]	Meta- analysis	15 studies	Mixed results on antibiotic resistance, with some studies indicating increasing trends for Antibiotic A and others showing stability for Antibiotic B. The meta-analysis concludes that there is no significant overall change in resistance.

Table 5: Comparison with existing literature
--

Our look back at the past revealed trends of drug resistance that are constantly changing. In study1 found signs that drug resistance was growing. This is what happens with antibiotic A. Even though it has been shown that antibiotic B is stable, it is essential to note the significant drop in antibiotic C resistance. Our study's subgroup analyses showed that medicines must be tailored to each patient's traits and their types of microbes. Our research shows that changes in the seasons significantly affect natural factors. The meta-analysis of changes in resistance by study 2 shows mixed results. This shows how varied the study that is being done is. These new findings have helped us learn more about how drug resistance works.

## Limitations of the Study

Before drawing any conclusions from the data, it is essential to consider many important things. Before starting a study that looks back, consider how the way records were kept might have affected how accurate and complete the data is. Because the study only looked at one healthcare center, it may only apply to a select group of people. Even though possible, the sample size might need to be more significant to identify weak trends or relationships. More information about a patient's problems and past antibiotic treatments might be required, making it harder to evaluate resistance trends fully. Because the study only lasted for a short time, worries about rising resistance or longer-term trends could be missed.

## **Implications for Clinical Practice**

This study reveals essential details that impact clinical practice and the treatment of antibiotics. The rise of antibiotic resistance heightens the need to monitor and be transparent about treatment methods closely. Doctors must be careful because microorganisms may become resistant to antibiotic A. Antibiotic B's long-term use is backed by its stability. In contrast, antibiotic C's falling resistance shows that it works better. Antibiotics could be changed based on the bacteria being treated and the time of year to make treatment more effective. Resistance rates vary by social group, which shows that focused efforts are needed to fix problems that aren't fair.

#### **Suggestions for Future Research**

All of the rules should be followed so that future studies can build on them and fill in our knowledge gaps to understand better how drug resistance works. More extended studies with a broader range of racial and ethnic groups and bigger sample sizes might reveal patterns of resistance that change over time. More research is needed to determine how external factors, treatment experiences, and other health problems can change response patterns. This is necessary for scientific progress. The findings can be applied to various healthcare situations and locations, as a comparative study shows. More study needs to be done on how antibiotic resistance works, especially in drug classes A and C, to focus treatments better. An essential part of evidencebased methods is the financial study of drug resistance and the clinical review of solutions that work.

#### Conclusion

In conclusion, our study of drug resistance trends shows constantly changing patterns affecting many clinical groups. According to the study, antibiotic resistance rose quickly, stayed the same with antibiotic B, and dropped significantly with antibiotic C. The study also showed that antibiotic C made resistance go down. Age reaction and microbiota makeup differ for each subgroup, which shows how important it is to treat each person individually. Seasonal effects show how complicated resistant dynamics are. It is helpful to compare current research with meta-analyses and future studies to understand drug resistance better. This study shows that to fight drug resistance, the healthcare industry must be constantly alert, use clever antibiotic management techniques, and create personalized drug approaches. Clinical practitioners may find the study's results helpful now and in the future. It also lays the groundwork for studies into drug resistance around the world.

#### Reference

- 1. P. Ioannou et al., "A six-year retrospective study of microbiological characteristics and antimicrobial resistance in specimens from a tertiary hospital's Surgical Ward," Antibiotics, vol. 12, no. 3, p. 490, Mar. 2023.
- T. Yangzom, D. C. Tsering, S. Kar, and J. Kapil, "Antimicrobial susceptibility trends among pathogens isolated from blood: A 6-year retrospective study from a tertiary care hospital in East Sikkim, India," Journal of Laboratory Physicians, vol. 12, no. 01, pp. 03–09, Mar. 2020.
- 3. N. Shi et al., "Bacteriological profile and antimicrobial susceptibility patterns of gramnegative bloodstream infection and risk factors associated with mortality and drug resistance: A retrospective study from Shanxi, China," In-

fection and Drug Resistance, vol. Volume 15, pp. 3561–3578, Jul. 2022.

- 4. T. Monteiro et al., "A five-year retrospective study shows increasing rates of antimicrobial drug resistance in Cabo Verde for both Staphylococcus aureus and escherichia coli," Journal of Global Antimicrobial Resistance, vol. 22, pp. 483–487, Sep. 2020.
- Walid. Q. Alali, W. AlFouzan, and R. Dhar, "Prevalence of antimicrobial resistance in gram-negative clinical isolates from a major secondary hospital in Kuwait: A retrospective descriptive study," Germs, vol. 11, no. 4, pp. 498–511, Dec. 2021.
- Ruedas-López et al., "Subspecies distribution and antimicrobial susceptibility testing of mycobacterium abscessus clinical isolates in Madrid, Spain: A retrospective multicenter study," Microbiology Spectrum, vol. 11, no. 3, Jun. 2023.
- Z. O. Elifranji et al., "Microbiological profile and drug resistance analysis of postoperative infections following orthopedic surgery: A 5year retrospective review," Advances in Orthopedics, vol. 2022, pp. 1–9, Jul. 2022.
- M. Hailemariam et al., "Major bacterial isolate and antibiotic resistance from routine clinical samples in southern Ethiopia," Scientific Reports, vol. 11, no. 1, Oct. 2021.
- G. S. Parmar, A. K. Meena, P. Borde, and S. Prasad, "Microbial keratitis and antibiotic sensitivity patterns: A retrospective analysis at a Tertiary Center in Central India," Indian Journal of Ophthalmology, vol. 71, no. 6, pp. 2455–2459, Jun. 2023.
- T. A. Hafiz et al., "A two-year retrospective study of multidrug-resistant Acinetobacter baumannii respiratory infections in critically ill patients: Clinical and microbiological findings," Journal of Infection and Public Health, vol. 16, no. 3, pp. 313–319, Mar. 2023.
- 11. N. M. Sheikh Omar et al., "Retrospective evaluation of nosocomial bacterial infections and their antimicrobial resistance patterns among hospitalized patients in Mogadishu, Somalia," Infection and Drug Resistance, vol. Volume 16, pp. 705–720, Feb. 2023.
- M. Daji, T. I. Ade, H. S. Cletus, A. M. Bello, and P. Joseph, "Antimicrobial resistance pattern of clinical isolates of pseudomonas aeruginosa from urinary tract infections in Wukari, Taraba State, Nigeria," Journal of Biochemistry, Microbiology and Biotechnology, vol. 10, no. 2, pp. 25–28, Dec. 2022.
- H. Alkofide et al., "Multidrug-resistant and extensively drug-resistant Enterobacteriaceae: Prevalence, treatments, and outcomes – A retrospective cohort study," Infection and Drug Resistance, vol. Volume 13, pp. 4653–4662, Dec. 2020. doi:10.2147/idr.s283488

#### International Journal of Pharmaceutical and Clinical Research

- F. Yang, V. Huang, J. Samaroo-Campbell, and M. Augenbraun, "Multi-drug resistant pseudomonas aeruginosa: A 2019–2020 single center retrospective case control study," Infection Prevention in Practice, vol. 5, no. 3, p. 100296, Sep. 2023.
- 15. K. Jepsen et al., "Prevalence and antibiotic susceptibility trends of periodontal pathogens in the subgingival microbiota of German periodontitis patients: A retrospective surveillance study," Journal of Clinical Periodontology, vol. 48, no. 9, pp. 1216–1227, Jun. 2021.